GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Diplomat Pharmacy Inc (NYSE:DPLO) » Definitions » Sloan Ratio %

Diplomat Pharmacy (Diplomat Pharmacy) Sloan Ratio % : -63.68% (As of Sep. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Diplomat Pharmacy Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Diplomat Pharmacy's Sloan Ratio for the quarter that ended in Sep. 2019 was -63.68%.

As of Sep. 2019, Diplomat Pharmacy has a Sloan Ratio of -63.68%, indicating there is a warning stage of accrual build up.


Diplomat Pharmacy Sloan Ratio % Historical Data

The historical data trend for Diplomat Pharmacy's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diplomat Pharmacy Sloan Ratio % Chart

Diplomat Pharmacy Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Sloan Ratio %
Get a 7-Day Free Trial 20.62 30.74 7.54 26.47 -22.09

Diplomat Pharmacy Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.50 -22.09 -21.43 -37.61 -63.68

Competitive Comparison of Diplomat Pharmacy's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Diplomat Pharmacy's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diplomat Pharmacy's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Diplomat Pharmacy's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Diplomat Pharmacy's Sloan Ratio % falls into.



Diplomat Pharmacy Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Diplomat Pharmacy's Sloan Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2018 )-Cash Flow from Operations (A: Dec. 2018 )
-Cash Flow from Investing (A: Dec. 2018 ))/Total Assets (A: Dec. 2018 )
=(-302.269-35.042
--11.235)/1476.359
=-22.09%

Diplomat Pharmacy's Sloan Ratio for the quarter that ended in Sep. 2019 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2019 )
=(-649.068-109.88
--18.563)/1162.603
=-63.68%

Diplomat Pharmacy's Net Income for the trailing twelve months (TTM) ended in Sep. 2019 was -298.025 (Dec. 2018 ) + -14.301 (Mar. 2019 ) + -159.462 (Jun. 2019 ) + -177.28 (Sep. 2019 ) = $-649 Mil.
Diplomat Pharmacy's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2019 was 1.835 (Dec. 2018 ) + 23.652 (Mar. 2019 ) + 43.098 (Jun. 2019 ) + 41.295 (Sep. 2019 ) = $110 Mil.
Diplomat Pharmacy's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2019 was 6.474 (Dec. 2018 ) + -7.723 (Mar. 2019 ) + -5.808 (Jun. 2019 ) + -11.506 (Sep. 2019 ) = $-19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diplomat Pharmacy  (NYSE:DPLO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2019, Diplomat Pharmacy has a Sloan Ratio of -63.68%, indicating there is a warning stage of accrual build up.


Diplomat Pharmacy Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Diplomat Pharmacy's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Diplomat Pharmacy (Diplomat Pharmacy) Business Description

Traded in Other Exchanges
N/A
Address
4100 South Saginaw Street, Flint, MI, USA, 48507
Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.
Executives
Brian T Griffin director, officer: Chairman and CEO
David C Dreyer director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Regina M. Benjamin director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Benjamin Wolin director C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Jeffrey G Park director C/O DIPLOMAT PHARMACY, INC., 4100 S. SAGINAW ST., FLINT MI 48507
Sean Whelan director, officer: Chief Financial Officer C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Jeffrey M Rowe director, officer: EVP of Operations C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018

Diplomat Pharmacy (Diplomat Pharmacy) Headlines

From GuruFocus

Diplomat Using SMRxT Technology to Enhance Patient Care

By PRNewswire PRNewswire 04-26-2019

Diplomat Announces Review of Strategic Alternatives

By PRNewswire PRNewswire 08-09-2019